Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sweeping FDA Changes Could Have “Disastrous Consequences” For Biotech Investment

Executive Summary

Lowering the bar on drug approval standards would create a challenging environment for biotech investors, warned Jonathan Leff, a partner at the health care investment firm Deerfield, during the BIO CEO & Investor Conference.

Advertisement

Related Content

Trump’s Tweets On Drug Prices; Industry Says “Huh?”
US FDA Commissioner Search: Pharma’s Preferred Candidate Is Gottlieb
Trump Throws Pharma A Curve Ball On The Third Day Of J.P. Morgan
CMS Cancels Part B Demo Before HHS Secretary-Designate Price Does

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098237

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel